JP2020520948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520948A5 JP2020520948A5 JP2019564446A JP2019564446A JP2020520948A5 JP 2020520948 A5 JP2020520948 A5 JP 2020520948A5 JP 2019564446 A JP2019564446 A JP 2019564446A JP 2019564446 A JP2019564446 A JP 2019564446A JP 2020520948 A5 JP2020520948 A5 JP 2020520948A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- heart failure
- weeks
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509489P | 2017-05-22 | 2017-05-22 | |
| US62/509,489 | 2017-05-22 | ||
| PCT/US2018/033783 WO2018217684A1 (en) | 2017-05-22 | 2018-05-22 | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520948A JP2020520948A (ja) | 2020-07-16 |
| JP2020520948A5 true JP2020520948A5 (enExample) | 2021-07-26 |
Family
ID=62567841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564446A Pending JP2020520948A (ja) | 2017-05-22 | 2018-05-22 | 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200069644A1 (enExample) |
| EP (1) | EP3630097A1 (enExample) |
| JP (1) | JP2020520948A (enExample) |
| KR (1) | KR20200006595A (enExample) |
| CN (1) | CN110662538A (enExample) |
| AU (1) | AU2018273382A1 (enExample) |
| BR (1) | BR112019024185A2 (enExample) |
| CA (1) | CA3064291A1 (enExample) |
| CL (1) | CL2019003325A1 (enExample) |
| CO (1) | CO2019013015A2 (enExample) |
| EA (1) | EA201992704A1 (enExample) |
| IL (1) | IL270749A (enExample) |
| MX (1) | MX2019013926A (enExample) |
| PE (1) | PE20200402A1 (enExample) |
| WO (1) | WO2018217684A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2869129T3 (es) * | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
| KR20230084530A (ko) * | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
| CN119055775A (zh) * | 2022-07-30 | 2024-12-03 | 中国医学科学院阜外医院 | Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途 |
| CN118831080B (zh) * | 2024-09-24 | 2024-11-22 | 上海交通大学医学院附属仁济医院 | 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492552A2 (en) * | 2002-04-03 | 2005-01-05 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| NZ752095A (en) | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| KR101645015B1 (ko) * | 2014-03-11 | 2016-08-03 | 포항공과대학교 산학협력단 | Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물 |
-
2018
- 2018-05-22 MX MX2019013926A patent/MX2019013926A/es unknown
- 2018-05-22 EP EP18730584.2A patent/EP3630097A1/en not_active Withdrawn
- 2018-05-22 WO PCT/US2018/033783 patent/WO2018217684A1/en not_active Ceased
- 2018-05-22 AU AU2018273382A patent/AU2018273382A1/en not_active Abandoned
- 2018-05-22 JP JP2019564446A patent/JP2020520948A/ja active Pending
- 2018-05-22 CN CN201880033663.XA patent/CN110662538A/zh active Pending
- 2018-05-22 PE PE2019002437A patent/PE20200402A1/es unknown
- 2018-05-22 US US16/612,438 patent/US20200069644A1/en not_active Abandoned
- 2018-05-22 BR BR112019024185-0A patent/BR112019024185A2/pt not_active Application Discontinuation
- 2018-05-22 CA CA3064291A patent/CA3064291A1/en active Pending
- 2018-05-22 KR KR1020197037388A patent/KR20200006595A/ko not_active Withdrawn
- 2018-05-22 EA EA201992704A patent/EA201992704A1/ru unknown
-
2019
- 2019-11-18 IL IL270749A patent/IL270749A/en unknown
- 2019-11-20 CL CL2019003325A patent/CL2019003325A1/es unknown
- 2019-11-21 CO CONC2019/0013015A patent/CO2019013015A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004208615C1 (en) | Medicine for prevention of and treatment for arteriosclerosis and hypertension | |
| CN101374523B (zh) | 用于治疗糖尿病的二肽基肽酶抑制剂 | |
| CA2622608C (en) | Dipeptidyl peptidase inhibitors for treating diabetes | |
| NO342004B1 (no) | 2-[6-(3-amino-piperidin-1-yl)-3-metyl-2,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril for anvendelse som et medikament for behandling av diabetes, cancer, en autoimmun sykdom eller HIV infeksjon | |
| CZ303433B6 (cs) | Použití ramiprilu, ramiprilátu nebo jejich farmaceuticky prijatelných derivátu | |
| KR20160053990A (ko) | 피롤리딘 유도체 ＡＳ 옥시토신/바소프레신 Ｖ1ａ 수용체 길항제 | |
| JP2005527523A (ja) | ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド | |
| US20040122067A1 (en) | Treatment of chronic heart failure | |
| CZ313897A3 (cs) | Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan | |
| US20240366596A1 (en) | Treatment of hfpef in post-menopausal women with an sgc stimulator | |
| US20240285583A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| JP2025508932A5 (enExample) | ||
| TW201000097A (en) | Medicament for the prophylaxis or treament of hypertension | |
| WO2004091659A1 (ja) | 眼内血管新生性疾患の予防又は治療のための医薬 | |
| CN1809353B (zh) | 一种预防和治疗动脉硬化及高血压的药剂 | |
| JP2025517798A (ja) | ナトリウム （５－（４－ブロモフェニル）－６－（２－（（５－ブロモピリミジン－２－イル）オキシ）エトキシ）ピリミジン－４－イル）（スルファモイル）アミドの結晶形 | |
| DK2026796T3 (en) | Use of a vasopeptidase inhibitor to treat pulmonary arterial hypertension | |
| JPWO2023223951A5 (enExample) | ||
| US20040254228A1 (en) | Treatment of chronic heart failure | |
| UA81290C2 (en) | Use of telmisartan and simvastatin, pharmaceutical composition and treatment method | |
| HK1078490A (en) | Medicine for prevention of and treatment for arteriosclerosis and hypertension |